Condition 1: prediabetes. Condition 2: Vitamin D deficiency. Abnormal glucose tolerance test Vitamin D deficiency, unspecified
Conditions
Interventions
Intervention 1: Intervention group1: 1000 mg omega-3 [each capsule containing 180 mg eicosapentaenoic acid (EPA) and 120 mg docosahexaenoic acid (DHA)] twice a day + vitamin D placebo every 2 weeks fo
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 50 Years
Inclusion criteria
Inclusion criteria: Reproductive-aged women (age15-50 years) FBS 100-125 mg/ml? serum vitamin D level < 32 ng/mL BMI < 30
Exclusion criteria
Exclusion criteria: Diagnosed pathological conditions such as thyroid or para thyroid disorders, PCO, seizures, liver or kidney disease, neurological disorders, cancer, cardiovascular disease, type 1 or 2 diabetes, Sarcoidosis or other Granulomatous disorder Intakes vitamin D or omega-3 during the last 6 months Breast feeding, pregnant, and/or planning for pregnancy in the following 2 months Intake of drugs that interact with omega-3 [including aspirin or anticoagulants (warfarin, heparin)] or with vitamin D (such as cardiac glycosides, Cholestyramine, anticonvulsant drugs or thiazides) Taking herbal or chemical drugs that affect serum lipids or blood glucose level In case of taking prescribed supplements different from study protocol Unwillingness to provide blood sample during the initial or final visits or not to continue participating in research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycemic status[fasting blood sugar and insulin, homeostasis model assessment-insulin resistance (HOMA-IR), homeostasis model assessment-beta cell function (HOMA-B)]. Timepoint: at beginning and after 8 weeks intervention. Method of measurement: Blood sampling and calculating (HOMA-IR) and (HOMA-B).;Serum lipids (triglyceride, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, total cholesterol). Timepoint: at beginning and after 8 weeks intervention. Method of measurement: Blood sampling.;Scores of Depression Anxiety Stress Scale (DASS 21). Timepoint: at beginning and after 8 weeks intervention. Method of measurement: Depression Anxiety Stress Scale (DASS 21).;Score of Pittsburgh Sleep Quality Index (PSQI). Timepoint: at beginning and after 8 weeks intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI). | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: At beginning and after 8 weeks intervention. Method of measurement: Digital scale.;Body mass index (BMI). Timepoint: At beginning and after 8 weeks intervention. Method of measurement: It will be calculated using the height and weight measurements w/h2 (w: weight in kg and h: height in meters).;Systolic and diastolic blood pressure. Timepoint: At beginning and after 8 weeks intervention. Method of measurement: Digital manometer.;Waist circumference. Timepoint: At beginning and after 8 weeks intervention. Method of measurement: Nonelastic tape. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahrokh Dolatian
Shahid Beheshti University of Medical Sciences
Outcome results
None listed